Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells

Yuko Suzuki,1 Hideo Mogami,1 Hayato Ihara,1 and Tetsumei Urano1

1Department of Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan

We analyzed the secretory dynamics of tissue plasminogen activator (tPA) in EA.hy926 cells, an established vascular endothelial cell (VEC) line producing GFP-tagged tPA, using total internal reflection-fluorescence (TIR-F) microscopy. tPA-GFP was detected in small granules in EA.hy926 cells, the distribution of which was indistinguishable from intrinsically expressed tPA. Its secretory dynamics were unique, with prolonged (> 5 minutes) retention of the tPA-GFP on the cell surface, appearing as fluorescent spots in two-thirds of the exocytosis events. The rapid disappearance (mostly by 250 ms) of a domain-deletion mutant of tPA-GFP possessing only the signal peptide and catalytic domain indicates that the amino-terminal heavy chain of tPA-GFP is essential for binding to the membrane surface. The addition of PAI-1 dose-dependently facilitated the dissociation of membrane-retained tPA and increased the amounts of tPA-PAI-1 high-molecular-weight complexes in the medium. Accordingly, suppression of PAI-1 synthesis in EA.hy926 cells by siRNA prolonged the dissociation of tPA-GFP, whereas a catalytically inactive mutant of tPA-GFP not forming complexes with PAI-1 remained on the membrane even after PAI-1 treatment. Our results provide new insights into the relationship between exocytosed, membrane-retained tPA and PAI-1, which would modulate cell surface–associated fibrinolytic potential. (Blood. 2009;113:470-478)

Introduction

Tissue plasminogen activator (tPA) is a 68-kDa serine protease that cleaves a single peptide bond in plasminogen to generate plasmin, which subsequently dissolves fibrin clots in the vasculature.1 The expression of its activity is finely tuned by the amount of its specific inhibitor, plasminogen activator inhibitor-1 (PAI-1),2,3 which is present in molar excess over tPA in human plasma. Thus, only a relatively small fraction of tPA circulates in blood in a functionally active form. Therefore, not only an elevation of plasma concentration of PAI-1 but an impairment of tPA release results in decreased fibrinolytic activity, which is regarded as a risk factor for ischemic cardiovascular events.4,6 Although the enzymologic interactions of these 2 molecules in the fluid phase have been extensively studied, interactions at the interface between fluid-phase and solid-phase structures such as fibrin and the cell surface where functional fibrinolysis actually takes place are not fully elucidated.7

In blood, tPA is secreted primarily from vascular endothelial cells (VECs) as an active single-chain enzyme,8 in contrast to most other serine proteases involved in coagulation and fibrinolysis, which are secreted aszymogens. Facilitated secretion, therefore, is directly related to the enhancement of fibrinolytic activity, which protects the VEC surface from clot accumulation and maintains vascular patency. Clinically, impairment of acute tPA release is reported in atherosclerosis, hypertension, and cigarette smoking.9,11 VECs secrete tPA through both constitutive and regulated pathways13,17 from small secretory granules morphologically distinct from the larger Weibel-Palade bodies.10 Although the precise signaling pathways regulating tPA release have not been elucidated, G-protein–coupled activation and increased intracellular calcium signaling appear to be important.15,17 Recent advances in the use of fluorescent proteins, such as green fluorescent protein (GFP), have allowed us to visualize cellular events and cellular components in intact, living cells by monitoring fluorescence intensity and its localization within the cell. Several studies,19-21 mainly in excitable cells, used GFP-tagged secretory molecules to document in detail the dynamics of their release from their granules, using total internal reflection-fluorescence (TIR-F) microscopy. This technique uses evanescent-wave excitation only of the fluorophore present in the immediate vicinity of the plasma membrane.

Using a similar approach, we conducted the present study to analyze the exocytotic dynamics of tPA in VECs under nonstimulated conditions. Slow secretory kinetics of tPA-GFP were demonstrated in VECs that exocytosed tPA-GFP molecules that are retained at the site on the cell membrane where the granules opened, and for which the amino-terminal heavy chain of tPA was required. Furthermore, PAI-1 appears to facilitate the dissociation of membrane-retained tPA, which would therefore decrease cell surface–associated fibrinolytic potential. These results provide new insights into the functional interactions of tPA and PAI-1 on the VEC surface.

Methods

Plasmid construction

The cDNA fragment encoding the enhanced green fluorescent protein (EGFP) from pEGFP-N1 (Clontech, Palo Alto, CA) was subcloned into NheI/NorI sites of the pcDNA3.1(+) expression vector and designated...
GFP3.1. Total RNA from EA.hy926 cells was amplified by reverse-transcription–polymerase chain reaction (PCR) using the forward primer for the cDNA fragment encoding full-length human tPA including the stop codon (1686 bp) 5′-TTG AGC ATG ATG GCA AAG AGA GGG-3′ and the reverse primer 5′-T TGG ATC CTT CGG TGG CAT TGT GTC ACG AAT-3′. The PCR product was digested with NheI and BamHI and then subcloned into NheI/BamHI sites in GFP3.1 (tPA-GFP). A mutant tPA containing a Ser-to-Ala substitution at amino acid position 478 (tPA-S478A-GFP) was produced using tPA-GFP as a template and a QuikChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA). The forward and reverse primers were 5′-GGC TGC CAG GGC GGG GA GGA GGC CCC CTG TG-3′ and 5′-CAC CAG GGG GCC TCC CGC ATC GCC CTG GCA GGC-3′, respectively. A deletion mutant tPA-GFP (tPA-CD-GFP) was generated using a simple and rapid method by PCR.22 A pair of primers, 5′-ACC TGG GTC CTT CGG TCG CAT GTT and 5′-TTG GTA AGA TCT GGC TCC TCT-3′, was prepared for deleting tPA nucleotide positions 115 to 891 corresponding to amino acid position Val4-Ser262 (finger, epidermal growth factor-like, kringle 1, and kringle 2 domains; collectively FnEK1K2 domains, the so-called heavy chain).23 All plasmid vectors were sequenced and prepared under endotoxin-free conditions.

Cell culture and transfection
The human vascular endothelial cell line EA.hy926 was kindly provided by Dr Edgell.24 This cell line resembles cultured human VECs and has been shown to retain endothelial cell–specific functions in most respects, including their fibrinolytic characteristics.25 We cultured the cells in Dulbecco modified Eagle medium (DMEM; Sigma-Aldrich, St Louis, MO) supplemented with glucose at 4.5 g/L and 10% fetal bovine serum at 37°C and 5% CO2 in a humidified atmosphere. For fluorescence imaging, the cells were cultured on a 35-mm glass bottom dish (Asahi Techno Glass, Tokyo, Japan) and transfected with the plasmids by lipofection using TransIT-LT1 (Mirus, Madison, WI) at 100% confluence. Experiments were performed within 2 days of transient transfection.

Suppression of PAI-1 synthesis
Cells were grown to 80% to 90% confluence in 35-mm glass bottom dishes and transfected with 20 nM siRNA for PAI-1 no. 1: 5′-GUC ACA UAG CCA UCA CUC UTT (Sigma-Aldrich), no. 4: 5′-AAG CAC AAC UCC CUU AAG GUC TF,26 or siPerfect negative control (Sigma-Aldrich) using the N-TER Nanoparticle siRNA Transfection System (Sigma-Aldrich).

Solutions and materials
A HEPES-buffered solution (HBS) composed of 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2, 10 mM glucose, and 10 mM HEPES-NaOH (pH 7.3) was used in all imaging studies unless otherwise noted. In some experiments, 50 mM NaCl was replaced by 50 mM NH4Cl. Low-pH NaOH (pH 7.3) was used in all imaging studies unless otherwise noted. In the N-TER Nanoparticle siRNA Transfection System (Sigma-Aldrich) using the N-TER Nanoparticle siRNA Transfection System (Sigma-Aldrich).

Immunocytochemistry
tPA-GFP–expressing or nonexpressing EA.hy926 cells cultured on a coverslip were fixed with 4% paraformaldehyde in PBS for 30 minutes and permeabilized by 0.1% Triton X-100 for 15 minutes. After blocking with 2% bovine serum albumin, cells were stained with 5 μg/mL anti-tPA for 1 hour, followed by Alexa Fluor 488– or TRITC–conjugated anti-IgG immunoglobulin (Molecular Probes and Dako, Carpinteria, CA) for 1 hour. After being mounted on a glass microscope slide with Dako fluorescent mounting medium, the specimens were examined by both epifluorescence (epi-F) and TIR-F microscopy.

Western blotting and fibrin autography
Culture medium was collected after 1 or 24 hours and centrifuged at 3000g for 10 minutes to remove cell debris. It was then mixed with the sample buffer for SDS–polyacrylamide gel electrophoresis (PAGE). After separation by SDS-PAGE, protein bands were trans-blotted onto a nitrocellulose membrane. tPA-, PAI-1–, and GFP-related bands were then visualized by enhanced chemiluminescence (ECL) Western blotting and fibrin autography.

Results
tPA-GFP localizes in the secretory granules and is secreted into the medium in a functional form from VECs (EA.hy926 cells)
We first characterized tPA-GFP expressed in EA.hy926 cells. Its intracellular localization was visualized by both epi-F and TIR-F microscopy, and was compared with intrinsically expressed tPA in EA.hy926 cells. The latter was detected by anti-tPA antibody labeled with FITC in small, round secretory granules (Figure 1A) as reported by Emeis et al in human umbilical vein endothelial cells.
(HUVECs).\textsuperscript{18} tPA-GFP fluorescence was detected in similar small granules in EA.hy926 cells. It was also detected by anti-tPA antibody labeled with TRITC, and its distribution in EA.hy926 cells was indistinguishable from intrinsically expressed tPA, which was more clearly and distinctly visualized by TIR-F (Figure 1B).

We next characterized tPA-GFP enzymatic activity at 24 hours in culture medium from either nontransfected EA.hy926 cells or those transfected with tPA-GFP expression vector. Western blot analysis (Figure 1C) using anti-tPA antibody revealed a high-molecular-weight band, approximately 147 kDa, in culture medium from the tPA-GFP–expressing cells that was absent from controls. This band was also detected by anti-GFP antibody, suggesting that it corresponded to a tPA-GFP–PAI-1 complex. Bands corresponding to both free tPA-GFP and intrinsic tPA were not observed because of the high level of expression of PAI-1 in this cell line. The high-molecular-weight band was also visualized by fibrin zymography (Figure 1D), suggesting that tPA-GFP is enzymatically active, forming high-molecular-weight complexes with PAI-1 and developing lytic bands in plasminogen-rich fibrin gels. These results suggest that tPA-GFP was secreted in an active form into the supernatant from the granules that contained it, in the same way as the intrinsic tPA. Therefore, tPA-GFP appeared to be functional and thus to represent a suitable probe for investigating the secretory mechanism of tPA in VECs.

Sequential steps (recruitment, docking, opening, and release) of tPA-GFP secretory granular exocytosis are visualized by TIR-F microscopy

To investigate processes by which tPA-GFP was released from its secretory granules, we performed time-lapse analysis using TIR-F microscopy. This has the advantage that molecular events taking place near the plasma membrane can be analyzed, and has been applied mainly to excitable cells.\textsuperscript{19,21} TIR-F illuminates to a depth of 100 nm or lower from the glass coverslip into the specimen because the energy wave drops off exponentially with distance from the coverslip-specimen interface. Using this technique, several sequential steps leading to single granular exocytosis of tPA-GFP were visualized as changes of fluorescence intensities. First, the recruitment of tPA-GFP–containing granules to the evanescent field and subsequent docking to the plasma membrane were imaged as the appearance of a static fluorescent spot. Second, granular opening was recognized as a sudden increase in fluorescence due mainly to neutralization of acidic pH in tPA-GFP–containing granules by culture medium at neutral pH. Indeed, a spatial shift of tPA-GFP closer to the coverslip during granule opening also contributes to the increase in fluorescence. To confirm that the sudden increase in fluorescence does indeed represent the opening of tPA-GFP–containing granules, we analyzed simultaneous temporal profiles of fluorescence intensities of tPA-GFP and TRITC-conjugated anti-GFP antibody. Figure 2A shows that a sudden increase (arrowhead) in green fluorescence of tPA-GFP corresponded to a gradual increase in red fluorescence, indicating that TRITC-conjugated anti-GFP antibody present in the extracellular space accumulated in the single opened granular spot. Every opened granule showed this gradual accumulation of red fluorescence (72 granules from 9 cells in 5 independent experiments). Evidently, sudden brightening of the secretory granule containing fluorescent tPA signifies the connection of the interior of the granule with the extracellular space. Third, the release of the contents of the granules was recognized by a decrease in fluorescence intensity. Because this third step is itself composed of several distinct steps, it will be described in detail later. Thus, we defined these 3 sequential main stages of change in fluorescence intensity as reflecting the secretory process.

The third stage of the tPA-GFP secretory process (ie, cargo release into the extracellular space according to this definition) was more heterogeneous than the other 2 steps. To evaluate this, we attempted to estimate the kinetics of tPA-GFP release from opened granules. We calculated the time required for the fluorescence intensity to decline to half of its peak value during the exponential reduction period following the sudden brightening due to granule opening, which we designated $T_{1/2}$. The individual $T_{1/2}$ during the
tPA-GFP–releasing process varied widely from a maximum of 266 seconds to a minimum of 1.13 seconds. This was analyzed and plotted for 77 granules in 10 cells (Figure 2B,C). Notably, almost all the fluorescent spots of exocytosed tPA-GFP, even those with the shortest TF1/2, remained detectable during the entire recording period (4.7 minutes). Similar heterogeneity in the dynamics of fluorescent protein–labeled tPA release has also been described previously in bovine chromaffin cells31 and in insulin-producing MIN6 cells.32 However, the underlying mechanisms and reasons for this have not yet been determined.

tPA-GFP is retained on the membrane surface in a VEC-specific manner

The slow dimming of iPA-GFP fluorescence after granule opening was further analyzed. Several factors may contribute to this process: (1) diffusion of tPA-GFP from the site of the opened granule into the liquid phase; (2) diffusion of tPA-GFP into the plasma membrane but retention at the membrane surface (lateral diffusion); and (3) recapturing (granule resealing) and reacidification of tPA-GFP–containing granules. We first analyzed the last possibility and asked whether the postexocytotic spots of tPA-GFP are retained on the membrane surface. Taking advantage of GFP fluorescence quenching on acidification, we analyzed the effect of transiently exposing tPA-GFP–expressing EA.hy926 cells to Mes-buffered acidic pH solution (pH 5.5 solution, applied 3 times for 30 seconds every 5 minutes). The degree of fluorescence of a granule that had brightened once on opening (Figure 3A arrowhead) and was then in the process of dimming further decreased at pH 5.5 and was reversed on neutralization. This reversible dimming, detected as a relative fluorescence decrease more than 20%
(Figure 3B), persisted for as long as the fluorescent spots were detectable (tested on 67 granules in 6 cells; 5 independent experiments). This was longer than 5 minutes in 45 (67%) of these 67 granules. In contrast, we also traced unopened granules at this time (albeit very few of them because of their motility) and found that their relative changes of fluorescence intensity were not influenced by exposure to pH 5.5 (Figure 3C open triangles). These results indicate that the exocytosed tPA-GFP retained on the membrane surface during this observation period and that material is not recaptured. Further, we applied NH₄Cl as a source of NH₃ to membrane surface during this observation period and that material results indicate that the exocytosed tPA-GFP retained on the membrane surface without retrieval for more than 5 minutes in a VEC-specific manner. The dimming of tPA-GFP fluorescence after opening appeared to result mainly from diffusion of tPA-GFP from the site of the opened granule membrane into the fluid phase and/or plasma membrane nearby in VECs.

**FnEK1K2 domains are responsible for binding of tPA-GFP to the membrane surface**

To investigate the mechanism of the slow release of tPA-GFP after exocytosis, we constructed a mutant tPA lacking the heavy chain and possessing only the signal peptides and catalytic domain and fused this with GFP (tPA-CD-GFP). The heavy chain of tPA is composed of finger, epidermal growth factor-like, kringle1, and kringle2 (FnEK1K2) domains (Figure 5A), and especially Fn and K2 domains play an important role in binding to fibrin clots. The intracellular distribution of tPA-CD-GFP was similar to wild-type tPA-GFP in both epi-F and TIR-F microscopy imaging (Figure 5B). In wild-type, the reduction in fluorescence after rapid brightening in opened single secretory granules was slow (Video S1 [available on the Blood website; see the Supplemental Materials link at the top of the online article]: tPA-GFP at 1 Hz). In contrast, tPA-CD-GFP fluorescence disappeared immediately after opening, like a flashlight being turned off, and did not leave any fluorescent spots of postexocytotic tPA-CD-GFP (Video S2: tPA-CD-GFP at 1.4 Hz). When NH₄Cl solution was transiently applied to tPA-CD-GFP–expressing cells, all granule spots in the TIR-F area increased in brightness (270 granules in 6 cells), suggesting that tPA-CD-GFP molecules were not retained on the membrane surface but were present only in unopened granules. These results indicate that tPA-CD-GFP could not be retained on the membrane surface because of the lack of the FnEK1K2 domain. The reduction in fluorescence after opening in domain-deletion mutants of either Fn or K2 of tPA–GFP–expressing cells was also faster than that in wild-type (Figure S1), suggesting the importance of these domains in the binding.

To evaluate the rapid discharge of tPA-CD-GFP, we acquired images with a highly sensitive electron multiplier CCD (EM-CCD) camera to improve time resolution. Figure 5C shows the 32 frames per second (fps) sequences of tPA-CD-GFP discharge from a single granule. After granule opening shown at time 0 ms, fluorescence diffused and had mostly disappeared by 250 ms. In this short period of time, in contrast, the fluorescence of exocytosed wild-type tPA-GFP remained strong (Figure 5D). The rapid time course of disappearance of tPA-CD-GFP was similar to the exocytotic time course of neuropeptide Y (NPY)–GFP in PC12 cells. Therefore, FnEK1K2 domains appeared responsible for the binding of exocytosed tPA-GFP to the membrane surface as well as for the heterogeneous dynamics of the tPA release process.

**PAI-1 accelerates membrane surface–retained tPA dissociation**

Because tPA-GFP as well as intrinsic tPA were observed only as a complex with PAI-1, and essentially no free form was detected in the supernatant, we investigated the effects of PAI-1 on the
dynamics of tPA release using 3 different approaches: (1) supplementation with recombinant PAI-1, (2) use of a GFP-tagged mutant form of tPA, tPA-S478A-GFP, and (3) suppression of PAI-1 synthesis by siRNA. In the first approach, we analyzed the effect of recombinant PAI-1 (rPAI-1) in tPA-GFP–expressing EA.hy926 cells. T_{F1/2} values before and after the addition of 40 nM rPAI-1 were calculated. Although the frequency of granule opening during each of the 4.7-minute observation periods was similar (53 granules before addition and 55 granules after addition opened in 6 cells; 4 independent experiments), T_{F1/2} was significantly reduced on addition of 40 nM rPAI-1 (Figure 6A). This accelerated reduction in fluorescence intensity in postexocytotic spots after rPAI-1 treatment was also detected even after pretreatment with 400 nM receptor-associated protein (RAP), which antagonizes the binding of tPA and tPA-PAI-1 complex to the low-density lipoprotein receptor-related protein (LRP; Figure 6C). When the cells were incubated with rPAI-1 for 60 minutes, tPA increased in a dose-dependent manner in the supernatant only in the form of a complex with rPAI-1, as detected by fibrin autography (Figure 6B). PAI-1 appeared to facilitate the dissociation not only of tPA-GFP but also intrinsic tPA from the granule membrane surface by forming high-molecular-weight complexes. In the second approach, we constructed a GFP-tagged mutant form of tPA, tPA-S478A, in which Ser478 was substituted by Ala so as to be catalytically inactive and unable to form covalent complexes with PAI-1, and analyzed its exocytotic dynamics. Although the efficacy of expression of tPA-S478A-GFP and wild-type tPA-GFP was similar, the former did not appear in the culture medium after 24 hours either complexed with PAI-1 or in the free form (Figure 7A). The intracellular distribution of tPA-S478A-GFP and tPA-GFP was indistinguishable, as judged by epi-F. In contrast, however, TIR-F revealed much stronger fluorescence of tPA-S478A-GFP than wild type (Figure 7B), suggesting that it is present at higher concentrations near the plasma membrane. The secretory dynamics of tPA-S478A-GFP also differ from wild type (Video S3), and it remained attached to the membrane surface for a longer period of time after granules’ opening. Eventually it did diffuse away into the plasma membrane, because strong fluorescence was observed not only in secretory granular spots but also in the surrounding plasma membrane. The presence of large amounts of tPA-S478A-GFP on the exterior plasma membrane was further confirmed by the fact that the decreasing intensity of fluorescence in whole cells measured by epi-F image (dF_{cell}) was more pronounced for tPA-S478A-GFP than wild type when cells were exposed to pH 5.5 solution (Figure 7C). Lack of formation of high-molecular-weight complexes between tPA-S478A-GFP and PAI-1 seems to render detachment from the membrane surface difficult, which eventually resulted in its accumulation on the cell surface. Accordingly, exogenous PAI-1 did not affect the prolonged T_{F1/2} in single granules containing tPA-S478A-GFP (Figure 7D gray bars). In the third approach, to more clearly demonstrate the effect of exogenous rPAI-1 on membrane surface–retained tPA, EA.hy926 cells were treated with PAI-1 siRNA to negate the effects of intrinsically synthesized PAI-1. Transient transfection with 2 different sequences (nos. 1, 4) of 20 nM PAI-1 siRNA reduced the amount of free PAI-1 in the culture medium after 18 hours, although complexes with tPA did not change a great deal (Figure 7E). Under such conditions, T_{F1/2} was prolonged significantly in comparison with control siRNA–transfected cells (no. 1: 23.9 ± 3.56 seconds from 141 granules, no. 4: 23.0 ± 4.80 seconds from 40 granules vs control siRNA: 8.1 ± 0.47 seconds from 113 granules; P < .001; data given as means ± SE) (Figure 7F). These effects of PAI-1 siRNA were prevented by the addition of 40 nM rPAI-1 (Figure 7G), reverting to the values for nontreated EA.hy926 cells as shown in Figure 6A. PAI-1, therefore, appeared to regulate the amounts of cell surface–associated tPA on VECs by facilitating the dissociation of tPA from the cell surface.

**Discussion**

Here, we demonstrated unique, slow secretory dynamics of tPA in VECs. In EA.hy926 cells, tPA-GFP was retained as fluorescent spots on the membrane surface after secretory granule opening without any internalization for more than 5 minutes. This contrasts with the exocytotic dynamics of tPA-containing secretory granules in endocrine and neuronal cells where postexocytotic tPA granules are retrieved, as described by “kiss-and-run” or “cavicapture” models. In the present study, we showed for the first time that the FnEK1K2 domains in tPA molecule are responsible for the
retention of exocytosed tPA on the cell surface. Retention of the active form of tPA on the cell surface without retrieval may be beneficial for maintaining high fibrinolytic activity. Further, using 3 different approaches, we demonstrated that PAI-1, the primary inhibitor of tPA, facilitates tPA dissociation from the VEC surface and functions as principal determinant of fibrinolytic activity on VECs as well as in plasma.

A unique characteristic of the tPA-releasing process in VECs is the extended period during which exocytosed tPA is retained on the surface of the cell without either retrieval or internalization. This was confirmed by 2 distinct experiments. One is the quenching of fluorescence of tPA-GFP spots by transient application of pH 5.5 solution to tPA-GFP–expressing EA.hy926 cells. The quenching was observed only in the spots that had already opened and persisted for as long as the fluorescent spots were detected. Another finding, that RAP did not modify the kinetics of the disappearance of tPA-GFP from the membrane, may suggest that the internalization of tPA or tPA-PAI-1 through LRP is not the major mechanism mediating tPA disappearance from the membrane surface.

In VECs, exocytosis mechanisms have been intensively studied in other large rod-shaped regulated secretory granules, known as Weibel-Palade bodies (WPBs). WPBs contain von Willebrand factor (VWF), endothelin, interleukin-8, and several adhesion molecules such as P-selectin and CD63. Romani de Wit et al assessed the trafficking of WPBs during signal-mediated exocytosis in living VWF-GFP–infected HUVECs and showed that the granules were retained as extracellular patches after opening evoked by both Ca2+ and cAMP-mobilizing agonists. Similarly to our present results on tPA-GFP–containing granules, individual VWF-GFP patches remained visible for approximately 20 minutes. Although the precise mechanisms responsible for these phenomena have not been clarified yet, such sustained retention of cargos after exocytosis appears common to both tPA and VWF in VECs.

When a mutant tPA-GFP lacking FnEK1K2 domains (tPA-CD-GFP) was used, the fluorescence disappeared in as short as 250 ms without leaving any fluorescent spots. This confirms that FnEK1K2 domains are responsible for the retention of tPA molecules on the membrane. tPA is known to bind to fibrin and denatured proteins having cross beta structures, and to efficiently catalyze plasminogen activation in which finger and K2 domains are reported to be responsible. The K2 domain possesses so-called lysine-binding sites (LBSs), and binds to proteins bearing C-terminal lysine either on cell membranes or in plasma. It now appears that FnEK1K2 domains, especially finger and K2 domains, are also responsible for the retention of postexocytic tPA molecules on the cell surface.

Although the FnEK1K2 domains of the tPA molecule are responsible for its retention on the membrane surface, no plasma membrane–associated tPA-binding factor has been identified in the present study. Among several proteins known to bind to tPA, annexin A2 is a particularly good candidate because it binds both tPA and plasminogen, and thereby facilitates plasmin generation on the endothelial cell surface. In most previous studies, however, direct interactions between annexin A2 and intrinsically generated and exocytosed tPA were not investigated. We analyzed possible binding of exocytosed tPA-GFP to annexin A2 on the surface of EA.hy926 cells. However, we failed to demonstrate colocalization of tPA-GFP with intrinsically generated annexin A2 either by immunocytochemistry or by using monomeric red fluorescent protein (mRFP)–tagged annexin A2 in EA.hy926 cells (data not shown). We hypothesize, therefore, that de novo synthesized tPA is present in the secretory granules and/or membrane surface bound via FnEK1K2 domains to unidentified factors other than annexin A2 even after exocytosis. Another possibility that exocytosed tPA binds to the matrix in the localized area is also not excluded, and further study is needed to identify the binding factor for tPA.

This sustained retention of tPA may be beneficial for maintaining functional fibrinolytic activity, because the secreted single-chain tPA is enzymatically active and the VEC surface is the site where fibrinolytic components assemble and mediate their functions. We successfully demonstrated the cell surface–retained intrinsic tPA activity after suppression of PAI-1 synthesis by siRNA transfection in EA.hy926 cells, which was totally inhibited by supplemented rPAI-1 (Figure S2). PAI-1 seems to suppress tPA activity not only in the fluid phase but also in solid-phase structures, on the cell surface, by facilitating the dissociation of membrane-retained intrinsic tPA. The facilitated dissociation of tPA-GFP by supplemental rPAI-1 was more clearly shown when intrinsic PAI-1 synthesis was suppressed by siRNA, suggesting that
disappearance of tPA-GFP, which was slow as shown in the present study, was still under the control of intrinsically generated PAI-1 in EA.hy926 cells. Another finding, that tPA-S478A-GFP stayed on the cell membrane for a long period, suggests that PAI-1 is the principle modifier of both the duration and amount of tPA retained on the cell membrane. This notion is in agreement with a well-established concept that elevated plasma PAI-1 levels, due mainly to obesity and insulin resistance, are risk factors for cardiovascular events. Decreased amounts of tPA retained at the VEC surface because of an excess of PAI-1 in plasma are one possible mechanism of hypofibrinolysis under pathological conditions.

As well as their ability to secrete tPA, VECs perform a variety of functions that regulate vascular tone, coagulation, fibrinolysis, and inflammation. VEC dysfunction is characterized by vasconstriction, thrombus formation, impaired fibrinolysis, and expression of adhesion molecules. Oliver et al reviewed the complexity of vascular biology in VEC dysfunction and concluded that some conditions associated with reduced tPA release are not necessarily accompanied by impaired endothelial-dependent vasodilation. They also discuss the possibility that under certain circumstances, reduced tPA release may be a more sensitive marker of endothelial dysfunction than endothelium-dependent vasomotion, for example in smokers and patients with hypertension. To date, tPA release is recognized only by an increase in tPA concentration in plasma. However, tPA retention time on the cell surface, defined here as $T_{1/2}$, would reflect fibrinolytic potency more directly than plasma tPA, and might also be an important indicator of VEC function. Evaluating tPA retention time in controlled secretion induced by various agonists including shear stress will be required to verify its significance for VEC function.

Acknowledgments

This work was supported by a Grant-in-Aid for Scientific Research (C: 19590858 [Y.S.] and C: 18590204 [T.U.]) from the Japan Society for the Promotion of Science (JSPS), a Japan Heart Foundation Research Grant (Y.S.), a grant from the Smoking Research Foundation (T.U.), and a grant from the Inamori Foundation (Y.S.).

Authorship

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Yuko Suzuki, 1-20-1, Handa-yama, Higashikus, Hamamatsu, 431-3192, Japan; e-mail: seigan@hama-med.ac.jp.

References


Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells

Yuko Suzuki, Hideo Mogami, Hayato Ihara and Tetsumei Urano